Summary of findings table ‐ Rifaximin vs placebo or no intervention
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes onlyRR 2.79 [0.44, 17.78]6 studies · 639 participantsVery low